Dr. Bupathi discusses JAVELIN Bladder 100 trial of maintenance avelumab
Manojkumar Bupathi, MD, MS, a medical oncologist at Rocky Mountain Cancer Centers, highlights the significance of the phase 3 JAVELIN Bladder 100 trial, in which patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy were randomized to best supportive care (BSC) with or without maintenance avelumab (Bavencio).
The FDA approved avelumab in this setting based on the JAVELIN Bladder 100 results, which showed a median overall survival of 21.4 months with avelumab plus BSC compared with 14.3 months with BSC alone. This 7.1-month benefit translated to a 31% reduction in the risk of death (HR, 0.69; 95% CI, 0.56-0.86; P <.001).
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
